By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Research findings on Biomaterials are discussed in a new report. According to news reporting originating in Winston Salem, North Carolina, by NewsRx journalists, research stated, "Treatment of the disrupted digital flexor tendon is troublesome because of the lack of sufficient healing capacity and the formation of adhesions. Sustained gene delivery may be a promising approach of modulating gene expression in enhancing tendon healing and decreasing adhesions."
The news reporters obtained a quote from the research from Wake Forest University, "In this study, a microRNA-based RNAi plasmid was used to specifically silence the expression of TGF-beta 1 gene associated with scar and adhesion formation in the flexor tendons. The miRNA plasmids were complexed with polylactic-co-glycolic acid (PLGA) nanoparticles to form nanoparticle/TGF-beta 1 miRNA plasmid (nanoparticle/plasmid) complexes. In vitro and in vivo transfection efficiencies experiments against tenocytes revealed that nanoparticle/plasmid complexes have significantly superior transfection efficiency over the lipofectamine/plasmid complexes. The gene and protein expression associated with adhesion of tendon treated with nanoparticle/plasmid complexes were evaluated by real-time PCR and immunoblotting. The grading of adhesions for tendons treated with nanoparticle/plasmid complexes was less severe than that treated with the nanoparticle/mock plasmid complexes."
According to the news reporters, the research concluded: "However, the ultimate strength of repaired tendons treated with nanoparticle/plasmid complexes was significantly lower than that of tendons treated with the nanoparticle/mock plasmid complexes."
For more information on this research see: Nanoparticle-mediated delivery of TGF-beta 1 miRNA plasmid for preventing flexor tendon adhesion formation. Biomaterials, 2013;34(33):8269-8278. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news correspondents report that additional information may be obtained by contacting Y.L. Zhou, Wake Forest Univ Hlth Sci, Wake Forest Inst Regenerat Med, Winston Salem, NC 27157, United States. Additional authors for this research include L.Z. Zhang, W.X. Zhao, Y.F. Wu, C.L. Zhu and Y.M. Yang (see also Biomaterials).
Keywords for this news article include: Biotechnology, Biomaterials, Gene Therapy, Winston Salem, United States, North Carolina, Bioengineering, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC